A class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc., alleging the company made materially false and misleading statements regarding the efficacy and safety profile of setrusumab, an investigational treatment for Osteogenesis Imperfecta. According to the complaint, Ultragenyx allegedly overstated confidence in interim analysis results derived from uncontrolled Phase II data while failing to adequately disclose risks identified during Phase III clinical trials.
The lawsuit names investors who purchased Ultragenyx securities during the period between August 3, 2023 and December 26, 2025 as potential class members. The allegations center on claims that the company's public statements misrepresented the drug candidate's therapeutic potential and trial performance, potentially causing financial losses for shareholders. The litigation follows the typical path for securities cases involving alleged disclosure violations.
Investors seeking to participate in the class action have until April 6, 2026 to submit a lead plaintiff application. The case is being handled by Bronstein, Gewirtz & Grossman LLC. Shareholders who believe they suffered losses due to the alleged misstatements are encouraged to contact counsel for additional information regarding eligibility and participation requirements.